Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822404 | 1.00 | CHRM2 (0.51) | CHRM2LMNAGAASIGMAR1KDM4E | |
| SCHEMBL19959702 | 0.88 | CYP2D6 (0.49) | CHRM2LMNAGAASIGMAR1KDM4E | |
| SCHEMBL17101375 | 0.87 | ALDH1A1 (0.52) | CHRM2LMNAGAASIGMAR1KDM4E | |
| SCHEMBL2953304 | 0.78 | CYP2D6 (0.55) | CHRM2SIGMAR1ALDH1A1SMN1; SMN2OPRL1 | |
| SCHEMBL11374272 | 0.77 | CYP2D6 (0.53) | CHRM2LMNASIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11370652 | 0.74 | CYP2D6 (0.60) | CHRM2SIGMAR1ALDH1A1SMN1; SMN2OPRL1 | |
| SCHEMBL1681858 | 0.74 | CHRM2 (0.48) | CHRM2LMNAGAASIGMAR1ALDH1A1 | |
| Bromide SCHEMBL1681877 | 0.73 | CHRM2 (0.47) | CHRM2LMNAGAASIGMAR1ALDH1A1 | |
| SCHEMBL2313255 | 0.73 | KDM4E (0.67) | LMNAGAASIGMAR1KDM4EALDH1A1 | |
| SCHEMBL28895784 | 0.72 | ALDH1A1 (0.66) | LMNAGAASIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-110903306-B | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| EP-3271358-B1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| EP-3271358-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | Heptares Therapeutics Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| EP-3119396-A1 | MUSCARINIC RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016147011-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016147011-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-09-22 | — | — | WO | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885LMNA 2124/4885GAA 3350/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885LMNA 2166/4885GAA 3401/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885LMNA 2166/4885GAA 3401/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885LMNA 2166/4885GAA 3401/4885 |
| US-20180072727-A1 | SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | CHRM2 2/4885LMNA 1718/4885GAA 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.